Contact
      Please use this form to send email to PR contact of this press release:
      
      LATITUDE Pharmaceuticals Develops an SC/IM Injectable Remdesivir Formulation
    
      TO:
      
      Matthew A. Singer, PhD
      
      LATITUDE Pharmaceuticals Inc.
      
      +1 858-342-2065